1 869 136 CHRONIC AGOMELATINE TREATMENT CORRECTS BEHAVIORAL, CELLULAR, AND BIOCHEMICAL ABNORMALITIES INDUCED BY PRENATAL STRESS IN RATS. RATIONALE AND OBJECTIVES: THE RAT MODEL OF PRENATAL RESTRAINT STRESS (PRS) REPLICATES FACTORS THAT ARE IMPLICATED IN THE ETIOLOGY OF ANXIOUS/DEPRESSIVE DISORDERS. WE USED THIS MODEL TO TEST THE THERAPEUTIC EFFICACY OF AGOMELATINE, A NOVEL ANTIDEPRESSANT THAT BEHAVES AS A MIXED MT1/MT2 MELATONIN RECEPTOR AGONIST/5-HT(2C) SEROTONIN RECEPTOR ANTAGONIST. RESULTS: ADULT PRS RATS SHOWED BEHAVIORAL, CELLULAR, AND BIOCHEMICAL ABNORMALITIES THAT WERE CONSISTENT WITH AN ANXIOUS/DEPRESSIVE PHENOTYPE. THESE INCLUDED AN INCREASED IMMOBILITY IN THE FORCED SWIM TEST, AN ANXIETY-LIKE BEHAVIOR IN THE ELEVATED PLUS MAZE, REDUCED HIPPOCAMPAL LEVELS OF PHOSPHORYLATED CAMP-RESPONSIVE ELEMENT BINDING PROTEIN (P-CREB), REDUCED HIPPOCAMPAL LEVELS OF MGLU2/3 AND MGLU5 METABOTROPIC GLUTAMATE RECEPTORS, AND REDUCED NEUROGENESIS IN THE VENTRAL HIPPOCAMPUS, THE SPECIFIC PORTION OF THE HIPPOCAMPUS THAT ENCODES MEMORIES RELATED TO STRESS AND EMOTIONS. ALL OF THESE CHANGES WERE REVERSED BY A 3- OR 6-WEEK TREATMENT WITH AGOMELATINE (40-50 MG/KG, I.P., ONCE A DAY). REMARKABLY, AGOMELATINE HAD NO EFFECT IN AGE-MATCHED CONTROL RATS, THEREBY BEHAVING AS A "DISEASE-DEPENDENT" DRUG. CONCLUSIONS: THESE DATA INDICATE THAT AGOMELATINE DID NOT ACT ON INDIVIDUAL SYMPTOMS BUT CORRECTED ALL ASPECTS OF THE PATHOLOGICAL EPIGENETIC PROGRAMMING TRIGGERED BY PRS. OUR FINDINGS STRONGLY SUPPORT THE ANTIDEPRESSANT ACTIVITY OF AGOMELATINE AND SUGGEST THAT THE DRUG IMPACTS MECHANISMS THAT LIE AT THE CORE OF ANXIOUS/DEPRESSIVE DISORDERS. 2011 2 6266 26 THE NEUROBIOLOGY OF SUICIDE. THE STRESS-DIATHESIS MODEL POSITS THAT SUICIDE IS THE RESULT OF AN INTERACTION BETWEEN STATE-DEPENDENT (ENVIRONMENTAL) STRESSORS AND A TRAIT-LIKE DIATHESIS OR SUSCEPTIBILITY TO SUICIDAL BEHAVIOUR, INDEPENDENT OF PSYCHIATRIC DISORDERS. FINDINGS FROM POST-MORTEM STUDIES OF THE BRAIN AND FROM GENOMIC AND IN-VIVO NEUROIMAGING STUDIES INDICATE A BIOLOGICAL BASIS FOR THIS DIATHESIS, INDICATING THE IMPORTANCE OF NEUROBIOLOGICAL SCREENING AND INTERVENTIONS, IN ADDITION TO COGNITIVE AND MOOD INTERVENTIONS, IN THE PREVENTION OF SUICIDE. EARLY-LIFE ADVERSITY AND EPIGENETIC MECHANISMS MIGHT EXPLAIN SOME OF THE LINK BETWEEN SUICIDE RISK AND BRAIN CIRCUITRY AND NEUROCHEMISTRY ABNORMALITIES. RESULTS FROM A RANGE OF STUDIES USING DIVERSE DESIGNS AND POST-MORTEM AND IN-VIVO TECHNIQUES SHOW IMPAIRMENTS OF THE SEROTONIN NEUROTRANSMITTER SYSTEM AND THE HYPOTHALAMIC-PITUITARY-ADRENAL AXIS STRESS-RESPONSE SYSTEM IN THE DIATHESIS FOR SUICIDAL BEHAVIOUR. THESE IMPAIRMENTS MANIFEST AS IMPAIRED COGNITIVE CONTROL OF MOOD, PESSIMISM, REACTIVE AGGRESSIVE TRAITS, IMPAIRED PROBLEM SOLVING, OVER-REACTIVITY TO NEGATIVE SOCIAL SIGNS, EXCESSIVE EMOTIONAL PAIN, AND SUICIDAL IDEATION, LEADING TO SUICIDAL BEHAVIOUR. BIOMARKERS RELATED TO THE DIATHESIS MIGHT HELP TO INFORM RISK-ASSESSMENT PROCEDURES AND TREATMENT CHOICE IN THE PREVENTION OF SUICIDE. 2014 3 881 36 CHRONIC CLOZAPINE TREATMENT RESTRAINS VIA HDAC2 THE PERFORMANCE OF MGLU2 RECEPTOR AGONISM IN A RODENT MODEL OF ANTIPSYCHOTIC ACTIVITY. PRECLINICAL FINDINGS IN RODENT MODELS POINTED TOWARD ACTIVATION OF METABOTROPIC GLUTAMATE 2/3 (MGLU2/3) RECEPTORS AS A NEW PHARMACOLOGICAL APPROACH TO TREAT PSYCHOSIS. HOWEVER, MORE RECENT STUDIES FAILED TO SHOW CLINICAL EFFICACY OF MGLU2/3 RECEPTOR AGONISM IN SCHIZOPHRENIA PATIENTS. WE PREVIOUSLY PROPOSED THAT LONG-TERM ANTIPSYCHOTIC MEDICATION RESTRICTED THE THERAPEUTIC EFFECTS OF THESE GLUTAMATERGIC AGENTS. HOWEVER, LITTLE IS KNOWN ABOUT THE MOLECULAR MECHANISM UNDERLYING THE POTENTIAL REPERCUSSION OF PREVIOUS ANTIPSYCHOTIC EXPOSURE ON THE THERAPEUTIC PERFORMANCE OF MGLU2/3 RECEPTOR AGONISTS. HERE WE SHOW THAT THIS MALADAPTIVE EFFECT OF ANTIPSYCHOTIC TREATMENT IS MEDIATED MOSTLY VIA HISTONE DEACETYLASE 2 (HDAC2). CHRONIC TREATMENT WITH THE ANTIPSYCHOTIC CLOZAPINE LED TO A DECREASE IN MOUSE FRONTAL CORTEX MGLU2 MRNA, AN EFFECT THAT REQUIRED EXPRESSION OF BOTH HDAC2 AND THE SEROTONIN 5-HT(2A) RECEPTOR. THIS TRANSCRIPTIONAL ALTERATION OCCURRED IN ASSOCIATION WITH HDAC2-DEPENDENT REPRESSIVE HISTONE MODIFICATIONS AT THE MGLU2 PROMOTER. WE FOUND THAT CHRONIC CLOZAPINE TREATMENT DECREASED VIA HDAC2 THE CAPABILITIES OF THE MGLU2/3 RECEPTOR AGONIST LY379268 TO ACTIVATE G-PROTEINS IN THE FRONTAL CORTEX OF MICE. CHRONIC CLOZAPINE TREATMENT BLUNTED THE ANTIPSYCHOTIC-RELATED BEHAVIORAL EFFECTS OF LY379268, AN EFFECT THAT WAS NOT OBSERVED IN HDAC2 KNOCKOUT MICE. MORE IMPORTANTLY, CO-ADMINISTRATION OF THE CLASS I AND II HDAC INHIBITOR SAHA (VORINOSTAT) PRESERVED THE ANTIPSYCHOTIC PROFILE OF LY379268 AND FRONTAL CORTEX MGLU2/3 RECEPTOR DENSITY IN WILD-TYPE MICE. THESE FINDINGS RAISE CONCERNS ON THE DESIGN OF PREVIOUS CLINICAL STUDIES WITH MGLU2/3 AGONISTS, PROVIDING THE RATIONALE FOR THE DEVELOPMENT OF HDAC2 INHIBITORS AS A NEW EPIGENETIC-BASED APPROACH TO IMPROVE THE CURRENTLY LIMITED RESPONSE TO TREATMENT WITH GLUTAMATERGIC ANTIPSYCHOTICS. 2019 4 513 28 ASSOCIATION OF SEROTONIN TRANSPORTER GENE ALUJB METHYLATION WITH MAJOR DEPRESSION, AMYGDALA RESPONSIVENESS, 5-HTTLPR/RS25531 POLYMORPHISM, AND STRESS. DNA METHYLATION PROFILES OF THE SEROTONIN TRANSPORTER GENE (SLC6A4) HAVE BEEN SHOWN TO ALTER SLC6A4 EXPRESSION, DRIVE ANTIDEPRESSANT TREATMENT RESPONSE AND MODIFY BRAIN FUNCTIONS. THIS STUDY INVESTIGATED WHETHER METHYLATION OF AN ALUJB ELEMENT IN THE SLC6A4 PROMOTOR WAS ASSOCIATED WITH MAJOR DEPRESSIVE DISORDER (MDD), AMYGDALA REACTIVITY TO EMOTIONAL FACES, 5-HTTLPR/RS25531 POLYMORPHISM, AND RECENT STRESS. MDD PATIENTS (N=122) AND HEALTHY CONTROLS (HC, N=176) UNDERWENT FMRI DURING AN EMOTIONAL FACE-MATCHING TASK. INDIVIDUAL SLC6A4 ALUJB METHYLATION PROFILES WERE ASCERTAINED AND ASSOCIATED WITH MDD, AMYGDALA REACTIVITY, 5-HTTLPR/RS25531, AND STRESS. SLC6A4 ALUJB METHYLATION WAS SIGNIFICANTLY LOWER IN MDD COMPARED TO HC AND IN STRESSED COMPARED TO LESS STRESSED PARTICIPANTS. LOWER ALUJB METHYLATION WAS PARTICULARLY FOUND IN 5-HTTLPR/RS25531 RISK ALLELE CARRIERS UNDER STRESS AND CORRELATED WITH LESS DEPRESSIVE EPISODES. FMRI ANALYSIS REVEALED A SIGNIFICANT INTERACTION OF ALUJB METHYLATION AND DIAGNOSIS IN THE AMYGDALA, WITH MDD PATIENTS SHOWING LOWER ALUJB METHYLATION ASSOCIATED WITH DECREASED AMYGDALA REACTIVITY. WHILE NO JOINT EFFECT OF ALUJB METHYLATION AND 5-HTTLPR/RS25531 EXISTED, RISK ALLELE CARRIERS SHOWED SIGNIFICANTLY INCREASED BILATERAL AMYGDALA ACTIVATION. THESE FINDINGS SUGGEST A ROLE OF SLC6A4 ALUJB METHYLATION IN MDD, AMYGDALA REACTIVITY, AND STRESS REACTION, PARTLY INTERWOVEN WITH 5-HTTLPR/RS25531 EFFECTS. PATIENTS WITH LOW METHYLATION IN CONJUNCTION WITH A SHORTER MDD HISTORY AND DECREASED AMYGDALA REACTIVITY MIGHT FEATURE A MORE STRESS-ADAPTIVE EPIGENETIC PROCESS, MAYBE VIA THEORETICALLY POSSIBLE ENDOGENOUS ANTIDEPRESSANT-LIKE EFFECTS. IN CONTRAST, PATIENTS WITH HIGHER METHYLATION MIGHT POSSIBLY SUFFER FROM IMPAIRED EPIGENETIC ADAPTION TO CHRONIC STRESS. FURTHER, THE 5-HTTLPR/RS25531 ASSOCIATION WITH AMYGDALA ACTIVATION WAS CONFIRMED IN OUR LARGE SAMPLE. 2018 5 2827 33 FLUOXETINE INCREASES HIPPOCAMPAL NEUROGENESIS AND INDUCES EPIGENETIC FACTORS BUT DOES NOT IMPROVE FUNCTIONAL RECOVERY AFTER TRAUMATIC BRAIN INJURY. THE SELECTIVE SEROTONIN REUPTAKE INHIBITOR FLUOXETINE INDUCES HIPPOCAMPAL NEUROGENESIS, STIMULATES MATURATION AND SYNAPTIC PLASTICITY OF ADULT HIPPOCAMPAL NEURONS, AND REDUCES MOTOR/SENSORY AND MEMORY IMPAIRMENTS IN SEVERAL CNS DISORDERS. IN THE SETTING OF TRAUMATIC BRAIN INJURY (TBI), ITS EFFECTS ON NEUROPLASTICITY AND FUNCTION HAVE YET TO BE THOROUGHLY INVESTIGATED. HERE WE EXAMINED THE EFFICACY OF FLUOXETINE AFTER A MODERATE TO SEVERE TBI, PRODUCED BY A CONTROLLED CORTICAL IMPACT. THREE DAYS AFTER TBI OR SHAM SURGERY, MICE WERE TREATED WITH FLUOXETINE (10 MG/KG/D) OR VEHICLE FOR 4 WEEKS. TO EVALUATE THE EFFECTS OF FLUOXETINE ON NEUROPLASTICITY, HIPPOCAMPAL NEUROGENESIS AND EPIGENETIC MODIFICATION WERE STUDIED. STEREOLOGIC ANALYSIS OF THE DENTATE GYRUS REVEALED A SIGNIFICANT INCREASE IN DOUBLECORTIN-POSITIVE CELLS IN BRAIN-INJURED ANIMALS TREATED WITH FLUOXETINE RELATIVE TO CONTROLS, A FINDING CONSISTENT WITH ENHANCED HIPPOCAMPAL NEUROGENESIS. EPIGENETIC MODIFICATIONS, INCLUDING AN INCREASE IN HISTONE 3 ACETYLATION AND INDUCTION OF METHYL-CPG-BINDING PROTEIN, A TRANSCRIPTION FACTOR INVOLVED IN DNA METHYLATION, WERE LIKEWISE SEEN BY IMMUNOHISTOCHEMISTRY AND QUANTITATIVE WESTERN IMMUNOBLOTS, RESPECTIVELY, IN BRAIN-INJURED ANIMALS TREATED WITH FLUOXETINE. TO DETERMINE IF FLUOXETINE IMPROVES NEUROLOGICAL OUTCOMES AFTER TBI, GAIT FUNCTION AND SPATIAL LEARNING AND MEMORY WERE ASSESSED BY THE CATWALK-ASSISTED GAIT TEST AND BARNES MAZE TEST, RESPECTIVELY. NO DIFFERENCES IN THESE PARAMETERS WERE SEEN BETWEEN FLUOXETINE- AND VEHICLE-TREATED ANIMALS. THUS WHILE FLUOXETINE ENHANCED NEUROPLASTICITY IN THE HIPPOCAMPUS AFTER TBI, ITS CHRONIC ADMINISTRATION DID NOT RESTORE LOCOMOTOR FUNCTION OR AMELIORATE MEMORY DEFICITS. 2011 6 1003 32 CHRONIC TREATMENT WITH FLUOXETINE INDUCES SEX-DEPENDENT ANALGESIC EFFECTS AND MODULATES HDAC2 AND MGLU2 EXPRESSION IN FEMALE MICE. GENDER AND SEX DIFFERENCES IN PAIN RECOGNITION AND DRUG RESPONSES HAVE BEEN REPORTED IN CLINICAL TRIALS AND EXPERIMENTAL MODELS OF PAIN. AMONG ANTIDEPRESSANTS, CONTRADICTORY RESULTS HAVE BEEN OBSERVED IN PATIENTS TREATED WITH SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS). THIS STUDY EVALUATED SEX DIFFERENCES IN RESPONSE TO THE SSRI FLUOXETINE AFTER CHRONIC ADMINISTRATION IN THE MOUSE FORMALIN TEST. ADULT MALE AND FEMALE CD1 MICE WERE INTRAPERITONEALLY INJECTED WITH FLUOXETINE (10 MG/KG) FOR 21 DAYS AND SUBJECTED TO PAIN ASSESSMENT. FLUOXETINE TREATMENT REDUCED THE SECOND PHASE OF THE FORMALIN TEST ONLY IN FEMALE MICE WITHOUT PRODUCING BEHAVIORAL CHANGES IN MALES. WE ALSO OBSERVED THAT FLUOXETINE WAS ABLE TO SPECIFICALLY INCREASE THE EXPRESSION OF METABOTROPIC GLUTAMATE RECEPTOR TYPE-2 (MGLU2) IN FEMALES. ALSO A REDUCED EXPRESSION OF THE EPIGENETIC MODIFYING ENZYME, HISTONE DEACETYLASE 2 (HDAC2), IN DORSAL ROOT GANGLIA (DRG) AND DORSAL HORN (DH) TOGETHER WITH AN INCREASE HISTONE 3 ACETYLATION (H3) LEVEL WAS OBSERVED IN FEMALES BUT NOT IN MALES. WITH THIS STUDY WE PROVIDE EVIDENCE THAT FLUOXETINE INDUCES SEX SPECIFIC CHANGES IN HDAC2 AND MGLU2 EXPRESSION IN THE DH OF THE SPINAL CORD AND IN DRGS AND SUGGESTS A MOLECULAR EXPLANATION FOR THE ANALGESIC EFFECTS IN FEMALE MICE. 2017 7 6170 31 THE HDAC INHIBITOR SAHA IMPROVES DEPRESSIVE-LIKE BEHAVIOR OF CRTC1-DEFICIENT MICE: POSSIBLE RELEVANCE FOR TREATMENT-RESISTANT DEPRESSION. MAJOR DEPRESSION IS A HIGHLY COMPLEX DISABLING PSYCHIATRIC DISORDER AFFECTING MILLIONS OF PEOPLE WORLDWIDE. DESPITE THE AVAILABILITY OF SEVERAL CLASSES OF ANTIDEPRESSANTS, A SUBSTANTIAL PERCENTAGE OF PATIENTS ARE UNRESPONSIVE TO THESE MEDICATIONS. A BETTER UNDERSTANDING OF THE NEUROBIOLOGY OF DEPRESSION AND THE MECHANISMS UNDERLYING ANTIDEPRESSANT RESPONSE IS THUS CRITICALLY NEEDED. WE PREVIOUSLY REPORTED THAT MICE LACKING CREB-REGULATED TRANSCRIPTION COACTIVATOR 1 (CRTC1) EXHIBIT A DEPRESSIVE-LIKE PHENOTYPE AND A BLUNTED ANTIDEPRESSANT RESPONSE TO THE SELECTIVE SEROTONIN REUPTAKE INHIBITOR FLUOXETINE. IN THIS STUDY, WE SIMILARLY SHOW THAT CRTC1(-/-) MICE ARE RESISTANT TO THE ANTIDEPRESSANT EFFECT OF CHRONIC DESIPRAMINE IN A BEHAVIORAL DESPAIR PARADIGM. SUPPORTING THE BLUNTED RESPONSE TO THIS TRICYCLIC ANTIDEPRESSANT, WE FOUND THAT DESIPRAMINE DOES NOT SIGNIFICANTLY INCREASE THE EXPRESSION OF BDNF AND NR4A1-3 IN THE HIPPOCAMPUS AND PREFRONTAL CORTEX OF CRTC1(-/-) MICE. EPIGENETIC REGULATION OF NEUROPLASTICITY GENE EXPRESSION HAS BEEN ASSOCIATED WITH DEPRESSION AND ANTIDEPRESSANT RESPONSE, AND HISTONE DEACETYLASE (HDAC) INHIBITORS HAVE BEEN SHOWN TO HAVE ANTIDEPRESSANT-LIKE PROPERTIES. HERE, WE SHOW THAT UNLIKE CONVENTIONAL ANTIDEPRESSANTS, CHRONIC SYSTEMIC ADMINISTRATION OF THE HDAC INHIBITOR SAHA PARTIALLY RESCUES THE DEPRESSIVE-LIKE BEHAVIOR OF CRTC1(-/-) MICE. THIS BEHAVIORAL EFFECT IS ACCOMPANIED BY AN INCREASED EXPRESSION OF BDNF, BUT NOT NR4A1-3, IN THE PREFRONTAL CORTEX OF THESE MICE, SUGGESTING THAT THIS EPIGENETIC INTERVENTION RESTORES THE EXPRESSION OF A SUBSET OF GENES BY ACTING DOWNSTREAM OF CRTC1. THESE FINDINGS SUGGEST THAT CRTC1 ALTERATIONS MAY BE ASSOCIATED WITH TREATMENT-RESISTANT DEPRESSION, AND SUPPORT THE INTERESTING POSSIBILITY THAT TARGETING HDACS MAY BE A USEFUL THERAPEUTIC STRATEGY IN ANTIDEPRESSANT DEVELOPMENT. 2016 8 1783 38 EFFECT OF AGOMELATINE ON MEMORY DEFICITS AND HIPPOCAMPAL GENE EXPRESSION INDUCED BY CHRONIC SOCIAL DEFEAT STRESS IN MICE. CHRONIC STRESS IS KNOWN TO INDUCE NOT ONLY ANXIETY AND DEPRESSIVE-LIKE PHENOTYPES IN MICE BUT ALSO COGNITIVE IMPAIRMENTS, FOR WHICH THE ACTION OF CLASSICAL ANTIDEPRESSANT COMPOUNDS REMAINS UNSATISFACTORY. IN THIS CONTEXT, WE INVESTIGATED THE EFFECTS OF CHRONIC SOCIAL DEFEAT STRESS (CSDS) ON ANXIETY-, SOCIAL- AND COGNITIVE-RELATED BEHAVIORS, AS WELL AS HIPPOCAMPAL BDNF, SYNAPTIC PLASTICITY MARKERS (PSD-95, SYNAPTOPHYSIN, SPINOPHILIN, SYNAPSIN I AND MAP-2), AND EPIGENETIC MODIFYING ENZYMES (MYST2, HDAC2, HDAC6, MLL3, KDM5B, DNMT3B, GADD45B) GENE EXPRESSION IN C57BL/6J MICE. CSDS FOR 10 DAYS PROVOKED LONG-LASTING ANXIOUS-LIKE PHENOTYPE IN THE OPEN FIELD AND EPISODIC MEMORY DEFICITS IN THE NOVEL OBJECT RECOGNITION TEST. WHILE TOTAL BDNF MRNA LEVEL WAS UNCHANGED, BDNF EXON IV, MAP-2, HDAC2, HDAC6 AND MLL3 GENE EXPRESSION WAS SIGNIFICANTLY DECREASED IN THE CSDS MOUSE HIPPOCAMPUS. IN CSDS MICE TREATED 3 WEEKS WITH 50 MG/KG/D AGOMELATINE, AN ANTIDEPRESSANT WITH MELATONERGIC RECEPTOR AGONIST AND 5-HT(2C) RECEPTOR ANTAGONIST PROPERTIES, THE ANXIOUS-LIKE PHENOTYPE WAS NOT REVERSED, BUT THE TREATMENT SUCCESSFULLY PREVENTED THE COGNITIVE IMPAIRMENTS AND HIPPOCAMPAL GENE EXPRESSION MODIFICATIONS. ALTOGETHER, THESE DATA EVIDENCED THAT, IN MICE, AGOMELATINE WAS EFFECTIVE IN ALLEVIATING STRESS-INDUCED ALTERED COGNITIVE FUNCTIONS, POSSIBLY THROUGH A MECHANISM INVOLVING BDNF SIGNALING, SYNAPTIC PLASTICITY AND EPIGENETIC REMODELING. 2017 9 2949 23 GENETIC AND EPIGENETIC CONSEQUENCE OF EARLY-LIFE SOCIAL STRESS ON DEPRESSION: ROLE OF SEROTONIN-ASSOCIATED GENES. EARLY-LIFE ADVERSITY CAUSED BY POOR SOCIAL BONDING AND DEPRIVED MATERNAL CARE IS KNOWN TO AFFECT MENTAL WELLBEING AND PHYSICAL HEALTH. IT IS A FORM OF CHRONIC SOCIAL STRESS THAT PERSISTS BECAUSE OF A NEGATIVE ENVIRONMENT, AND THE CONSEQUENCES ARE LONG-LASTING ON MENTAL HEALTH. THE PRESENCE OF SOCIAL STRESS DURING EARLY LIFE CAN HAVE AN EPIGENETIC EFFECT ON THE BODY, POSSIBLY RESULTING IN MANY COMPLEX MENTAL DISORDERS, INCLUDING DEPRESSION IN LATER LIFE. HERE, WE REVIEW THE EVIDENCE FOR EARLY-LIFE SOCIAL STRESS-INDUCED EPIGENETIC CHANGES THAT MODULATE JUVENILE AND ADULT SOCIAL BEHAVIOR (DEPRESSION AND ANXIETY). THIS REVIEW HAS A PARTICULAR EMPHASIS ON THE INTERACTION BETWEEN EARLY-LIFE SOCIAL STRESS AND GENETIC VARIATION OF SEROTONIN ASSOCIATE GENES INCLUDING THE SEROTONIN TRANSPORTER GENE (5-HTT; ALSO KNOWN AS SLC6A4), WHICH ARE KEY MOLECULES INVOLVED IN DEPRESSION. 2020 10 6062 22 THE DEVELOPMENTAL BASIS OF EPIGENETIC REGULATION OF HTR2A AND PSYCHIATRIC OUTCOMES. THE SEROTONIN RECEPTOR 5-HT2A (ENCODED BY HTR2A) IS AN IMPORTANT REGULATOR OF FETAL BRAIN DEVELOPMENT AND ADULT COGNITIVE FUNCTION. ENVIRONMENTAL SIGNALS THAT INDUCE EPIGENETIC CHANGES OF SEROTONIN RESPONSE GENES, INCLUDING HTR2A, HAVE BEEN IMPLICATED IN ADVERSE MENTAL HEALTH OUTCOMES. THE OBJECTIVE OF THIS PERSPECTIVE ARTICLE IS TO ADDRESS THE MEDICAL IMPLICATIONS OF HTR2A EPIGENETIC REGULATION, WHICH HAS BEEN ASSOCIATED WITH BOTH INFANT NEUROBEHAVIORAL OUTCOMES AND ADULT MENTAL HEALTH. ONGOING RESEARCH HAS IDENTIFIED A REGION OF THE HTR2A PROMOTER THAT HAS BEEN ASSOCIATED WITH A NUMBER OF MEDICAL OUTCOMES IN ADULTS AND INFANTS, INCLUDING BIPOLAR DISORDER, SCHIZOPHRENIA, CHRONIC FATIGUE SYNDROME, BORDERLINE PERSONALITY DISORDER, SUICIDALITY, AND NEUROBEHAVIORAL OUTCOMES. EPIGENETIC REGULATION OF HTR2A HAS BEEN STUDIED IN SEVERAL DIFFERENT TYPES OF TISSUES, INCLUDING THE PLACENTA. THE PLACENTA IS AN IMPORTANT SOURCE OF SEROTONIN DURING FETAL NEURODEVELOPMENT, AND PLACENTAL EPIGENETIC VARIATION OF HTR2A HAS BEEN ASSOCIATED WITH INFANT NEUROBEHAVIORAL OUTCOMES, WHICH MAY REPRESENT THE BASIS OF ADULT MENTAL HEALTH DISORDERS. FURTHER ANALYSIS IS NEEDED TO IDENTIFY INTRINSIC AND EXTRINSIC FACTORS THAT MODULATE HTR2A METHYLATION, AND THE MECHANISM BY WHICH THIS EPIGENETIC VARIATION INFLUENCES FETAL GROWTH AND LEADS TO ALTERED BRAIN DEVELOPMENT, MANIFESTING IN PSYCHIATRIC DISORDERS. 2014 11 3177 40 H3K9ME2 REGULATION OF BDNF EXPRESSION IN THE HIPPOCAMPUS AND MEDIAL PREFRONTAL CORTEX IS INVOLVED IN THE DEPRESSIVE-LIKE PHENOTYPE INDUCED BY MATERNAL SEPARATION IN MALE RATS. BACKGROUND: EARLY LIFE STRESS (ELS) INDUCES A DEPRESSIVE-LIKE PHENOTYPE AND INCREASES THE RISK OF DEPRESSION. BRAIN-DERIVED NEUROTROPHIC FACTOR (BDNF) HAS BEEN CONFIRMED TO BE INVOLVED IN THE PATHOPHYSIOLOGY OF DEPRESSION. HOWEVER, THE MECHANISM BY WHICH ELS ALTERS THE EPIGENETIC REGULATION OF BDNF AND CHANGES SUSCEPTIBILITY TO DEPRESSION HAS NOT BEEN FULLY CLARIFIED. METHODS: THE PRESENT STUDY USED MATERNAL SEPARATION (MS) AND CHRONIC UNPREDICTED MILD STRESS (CUMS) TO ESTABLISH AN MS ANIMAL MODEL AND A DEPRESSIVE ANIMAL MODEL. WE ASSESSED DEPRESSIVE-LIKE BEHAVIOURS, INCLUDING ANHEDONIA, LOCOMOTOR ACTIVITY, ANXIETY-LIKE BEHAVIOUR, AND SPATIAL MEMORY, USING THE SUCROSE PREFERENCE TEST, THE OPEN FIELD TEST, THE ELEVATED PLUS MAZE TEST, AND THE MORRIS WATER MAZE TEST. WE ALSO INVESTIGATED BDNF AND H3K9ME2 EXPRESSION IN THE HIPPOCAMPUS AND MEDIAL PREFRONTAL CORTEX (MPFC) BY IMMUNOHISTOCHEMISTRY, WESTERN BLOTTING, AND QPCR ANALYSIS. ADDITIONALLY, WE USED UNC0642, A SMALL MOLECULE INHIBITOR OF HISTONE METHYLTRANSFERASE (G9A), AS AN INTERVENTION. RESULTS: THE RESULTS SHOWED THAT CUMS INDUCED DEPRESSIVE-LIKE BEHAVIOURS IN RATS AND RESULTED IN INCREASED H3K9ME2 EXPRESSION AND DECREASED BDNF EXPRESSION IN THE HIPPOCAMPUS AND MPFC. MORE IMPORTANTLY, ADULT MS RATS EXPERIENCING CUMS HAD MORE SEVERE DEPRESSIVE BEHAVIOURS, HAD HIGHER EXPRESSION OF H3K9ME2 IN THE HIPPOCAMPUS AND MPFC, AND HAD LOWER EXPRESSION OF BDNF IN THE HIPPOCAMPUS AND MPFC. IN ADDITION, ADMINISTRATION OF THE G9A INHIBITOR REVERSED MOST OF THE CHANGES. CONCLUSIONS: OUR STUDY SUGGESTS THAT ELS CHANGED BDNF AND H3K9ME2 EXPRESSION IN THE RAT BRAIN, RESULTING IN A DEPRESSIVE-LIKE PHENOTYPE. 2021 12 5158 33 PRE-REPRODUCTIVE STRESS AND FLUOXETINE TREATMENT IN RATS AFFECT OFFSPRING A-TO-I RNA EDITING, GENE EXPRESSION AND SOCIAL BEHAVIOR. ADENOSINE TO INOSINE RNA EDITING IS AN EPIGENETIC PROCESS THAT ENTAILS SITE-SPECIFIC MODIFICATIONS IN DOUBLE-STRANDED RNA MOLECULES, CATALYZED BY ADENOSINE DEAMINASES ACTING ON RNA (ADARS). USING THE MULTIPLEX MICROFLUIDIC PCR AND DEEP SEQUENCING TECHNIQUE, WE RECENTLY SHOWED THAT EXPOSING ADOLESCENT FEMALE RATS TO CHRONIC UNPREDICTABLE STRESS BEFORE REPRODUCTION AFFECTS EDITING IN THE PREFRONTAL CORTEX AND AMYGDALA OF THEIR NEWBORN OFFSPRING, PARTICULARLY AT THE SEROTONIN RECEPTOR 5-HT2C (ENCODED BY HTR2C). HERE, WE USED THE SAME TECHNIQUE TO DETERMINE WHETHER POST-STRESS, PRE-REPRODUCTIVE MATERNAL TREATMENT WITH FLUOXETINE (5 MG/KG, 7 DAYS) REVERSES THE EFFECTS OF STRESS ON EDITING. WE ALSO EXAMINED THE MRNA EXPRESSION OF ADAR ENZYMES IN THESE REGIONS, AND ASKED WHETHER SOCIAL BEHAVIOR IN ADULT OFFSPRING WOULD BE ALTERED BY MATERNAL EXPOSURE TO STRESS AND/OR FLUOXETINE. MATERNAL TREATMENT WITH FLUOXETINE ALTERED HTR2C EDITING IN OFFSPRING AMYGDALA AT BIRTH, ENHANCED THE EXPRESSION OF HTR2C MRNA AND RNA EDITING ENZYMES IN THE PREFRONTAL CORTEX, AND REVERSED THE EFFECTS OF PRE-REPRODUCTIVE STRESS ON HTR2C EDITING IN THIS REGION. FURTHERMORE, MATERNAL FLUOXETINE TREATMENT ENHANCED DIFFERENCES IN EDITING OF GLUTAMATE RECEPTORS BETWEEN OFFSPRING OF CONTROL AND STRESS-EXPOSED RATS, AND LED TO ENHANCED SOCIAL PREFERENCE IN ADULT OFFSPRING. OUR FINDINGS INDICATE THAT PRE-GESTATIONAL FLUOXETINE TREATMENT AFFECTS PATTERNS OF RNA EDITING AND EDITING ENZYME EXPRESSION IN NEONATAL OFFSPRING BRAIN IN A REGION-SPECIFIC MANNER, IN INTERACTION WITH PRE-REPRODUCTIVE STRESS. OVERALL, THESE FINDINGS IMPLY THAT FLUOXETINE TREATMENT AFFECTS SEROTONERGIC SIGNALING IN OFFSPRING BRAIN EVEN WHEN TREATMENT IS DISCONTINUED BEFORE GESTATION, AND ITS EFFECTS MAY DEPEND UPON PRIOR EXPOSURE TO STRESS. 2018 13 4848 26 OPIOID-INDUCED STRUCTURAL AND FUNCTIONAL PLASTICITY OF MEDIUM-SPINY NEURONS IN THE NUCLEUS ACCUMBENS. OPIOID USE DISORDER (OUD) IS A CHRONIC RELAPSING CLINICAL CONDITION WITH TREMENDOUS MORBIDITY AND MORTALITY THAT FREQUENTLY PERSISTS, DESPITE TREATMENT, DUE TO AN INDIVIDUAL'S UNDERLYING PSYCHOLOGICAL, NEUROBIOLOGICAL, AND GENETIC VULNERABILITIES. EVIDENCE SUGGESTS THAT THESE VULNERABILITIES MAY HAVE NEUROCHEMICAL, CELLULAR, AND MOLECULAR BASES. KEY NEUROPLASTIC EVENTS WITHIN THE MESOCORTICOLIMBIC SYSTEM THAT EMERGE THROUGH CHRONIC EXPOSURE TO OPIOIDS MAY HAVE A DETERMINATIVE INFLUENCE ON BEHAVIORAL SYMPTOMS ASSOCIATED WITH OUD. IN PARTICULAR, STRUCTURAL AND FUNCTIONAL ALTERATIONS IN THE DENDRITIC SPINES OF MEDIUM SPINY NEURONS (MSNS) WITHIN THE NUCLEUS ACCUMBENS (NAC) AND ITS DOPAMINERGIC PROJECTIONS FROM THE VENTRAL TEGMENTAL AREA (VTA) ARE BELIEVED TO FACILITATE THESE BEHAVIORAL SEQUELAE. ADDITIONALLY, GLUTAMATERGIC NEURONS FROM THE PREFRONTAL CORTEX, THE BASOLATERAL AMYGDALA, THE HIPPOCAMPUS, AND THE THALAMUS PROJECT TO THESE SAME MSNS, PROVIDING AN ENRICHED TARGET FOR SYNAPTIC PLASTICITY. HERE, WE REVIEW LITERATURE RELATED TO NEUROADAPTATIONS IN NAC MSNS FROM DOPAMINERGIC AND GLUTAMATERGIC PATHWAYS IN OUD. WE ALSO DESCRIBE NEW FINDINGS RELATED TO TRANSCRIPTIONAL, EPIGENETIC, AND MOLECULAR MECHANISMS IN MSN PLASTICITY IN THE DIFFERENT STAGES OF OUD. 2021 14 3312 45 HIPPOCAMPAL AND BEHAVIORAL DYSFUNCTIONS IN A MOUSE MODEL OF ENVIRONMENTAL STRESS: NORMALIZATION BY AGOMELATINE. STRESS-INDUCED ALTERATIONS IN NEURONAL PLASTICITY AND IN HIPPOCAMPAL FUNCTIONS HAVE BEEN SUGGESTED TO BE INVOLVED IN THE DEVELOPMENT OF MOOD DISORDERS. IN THIS CONTEXT, WE INVESTIGATED IN THE HIPPOCAMPUS THE ACTIVATION OF INTRACELLULAR SIGNALING CASCADES, THE EXPRESSION OF EPIGENETIC MARKERS AND PLASTICITY-RELATED GENES IN A MOUSE MODEL OF STRESS-INDUCED HYPERACTIVITY AND OF MIXED AFFECTIVE DISORDERS. WE ALSO DETERMINED WHETHER THE ANTIDEPRESSANT DRUG AGOMELATINE, A MT1/MT2 MELATONERGIC RECEPTOR AGONIST/5-HT2C RECEPTOR ANTAGONIST, COULD PREVENT SOME NEUROBIOLOGICAL AND BEHAVIORAL ALTERATIONS PRODUCED BY STRESS. C57BL/6J MICE, EXPOSED FOR 3 WEEKS TO DAILY UNPREDICTABLE SOCIO-ENVIRONMENTAL STRESSORS OF MILD INTENSITY, WERE TREATED DURING THE WHOLE PROCEDURE WITH AGOMELATINE (50 MG KG(-1) PER DAY, INTRAPERITONEAL). STRESSED MICE DISPLAYED ROBUST INCREASES IN EMOTIONAL AROUSAL, VIGILANCE AND MOTOR ACTIVITY, TOGETHER WITH A REWARD DEFICIT AND A REDUCTION IN ANXIETY-LIKE BEHAVIOR. NEUROBIOLOGICAL INVESTIGATIONS SHOWED AN INCREASED PHOSPHORYLATION OF INTRACELLULAR SIGNALING PROTEINS, INCLUDING ATF1, CREB AND P38, IN THE HIPPOCAMPUS OF STRESSED MICE. DECREASED HIPPOCAMPAL LEVEL OF THE REPRESSIVE EPIGENETIC MARKS HDAC2 AND H3K9ME2, AS WELL AS INCREASED LEVEL OF THE PERMISSIVE MARK H3K9/14AC SUGGESTED THAT CHRONIC MILD STRESS WAS ASSOCIATED WITH INCREASED GENE TRANSCRIPTION, AND CLEAR-CUT EVIDENCE WAS FURTHER INDICATED BY CHANGES IN NEUROPLASTICITY-RELATED GENES, INCLUDING ARC, BCL2, BDNF, GDNF, IGF1 AND NEUROD1. TOGETHER WITH OTHER FINDINGS, THE PRESENT DATA SUGGEST THAT CHRONIC ULTRA-MILD STRESS CAN MODEL THE HYPERACTIVITY OR PSYCHOMOTOR AGITATION, AS WELL AS THE MIXED AFFECTIVE BEHAVIORS OFTEN OBSERVED DURING THE MANIC STATE OF BIPOLAR DISORDER PATIENTS. INTERESTINGLY, AGOMELATINE COULD NORMALIZE BOTH THE BEHAVIORAL AND THE MOLECULAR ALTERATIONS INDUCED BY STRESS, PROVIDING FURTHER INSIGHTS INTO THE MECHANISM OF ACTION OF THIS NEW GENERATION ANTIDEPRESSANT DRUG. 2014 15 6582 37 TRICHOSTATIN A, A HISTONE DEACETYLASE INHIBITOR, ALLEVIATES THE EMOTIONAL ABNORMALITY INDUCED BY MALADAPTATION TO STRESS IN MICE. RECENT REPORTS HAVE IMPLIED THAT ABERRANT BIOCHEMICAL PROCESSES IN THE BRAIN ARE FREQUENTLY ACCOMPANIED BY SUBTLE SHIFTS IN THE CELLULAR EPIGENETIC PROFILE THAT MIGHT UNDERLIE THE PATHOGENIC PROGRESSION OF PSYCHIATRIC DISORDERS. THE AIM OF THE PRESENT STUDY WAS TO EXAMINE THE EFFECT OF TRICHOSTATIN A (TSA), A HISTONE DEACETYLASE (HDAC) INHIBITOR, ON THE EMOTIONAL ABNORMALITY INDUCED BY MALADAPTATION TO STRESS IN MICE. MICE WERE EXPOSED TO REPEATED RESTRAINT STRESS FOR 240 MIN/DAY FOR 14 DAYS. WE APPLIED DOSING SCHEDULES. IN ONE SCHEDULE, FROM THE 3RD DAY OF STRESS EXPOSURE, MICE WERE TREATED WITH TSA (1650 MUM/4 MUL, I.C.V.) IMMEDIATELY AFTER THE DAILY EXPOSURE TO RESTRAINT STRESS. IN THE OTHER SCHEDULE, FROM THE 1ST DAY OF STRESS EXPOSURE, MICE WERE TREATED WITH TSA 2 H BEFORE EXPOSURE TO RESTRAINT STRESS. AFTER THE FINAL EXPOSURE TO RESTRAINT STRESS, THE EMOTIONALITY OF MICE WAS EVALUATED USING THE HOLE-BOARD TEST. MICE THAT WERE EXPOSED TO RESTRAINT STRESS FOR 240 MIN/DAY FOR 14 DAYS SHOWED A DECREASE IN HEAD-DIPPING BEHAVIOR. THIS DECREASED EMOTIONALITY OBSERVED IN STRESS-MALADAPTIVE MICE WAS SIGNIFICANTLY RECOVERED BY CHRONIC TREATMENT WITH TSA 2 H BEFORE DAILY EXPOSURE TO RESTRAINT STRESS, WHICH CONFIRMED THE DEVELOPMENT OF STRESS ADAPTATION. ON THE OTHER HAND, NO SUCH STRESS ADAPTATION WAS OBSERVED UNDER CHRONIC TREATMENT WITH TSA IMMEDIATELY AFTER DAILY STRESS EXPOSURE. A BIOCHEMICAL STUDY SHOWED THAT TRYPTOPHAN HYDROXYLASE, THE RATE-LIMITING ENZYME IN SEROTONIN (5-HT) SYNTHESIS, WAS INCREASED IN MIDBRAIN CONTAINING RAPHE NUCLEI OBTAINED FROM STRESS-ADAPTED MICE THAT WERE CHRONICALLY TREATED WITH TSA 2 H BEFORE DAILY STRESS EXPOSURE. THESE FINDINGS SUGGEST THAT AN HDAC INHIBITOR MAY HAVE A BENEFICIAL EFFECT ON STRESS ADAPTATION BY AFFECTING 5-HT NEURAL FUNCTION IN THE BRAIN AND ALLEVIATE THE EMOTIONAL ABNORMALITY UNDER CONDITIONS OF EXCESSIVE STRESS. 2022 16 3313 27 HIPPOCAMPAL BDNF IN PHYSIOLOGICAL CONDITIONS AND SOCIAL ISOLATION. EXPOSURE OF AN ORGANISM TO CHRONIC PSYCHOSOCIAL STRESS MAY AFFECT BRAIN-DERIVED NEUROTROPHIC FACTOR (BDNF) EXPRESSION THAT HAS BEEN IMPLICATED IN THE ETIOLOGY OF PSYCHIATRIC DISORDERS, SUCH AS DEPRESSION. GIVEN THAT DEPRESSION IN HUMANS HAS BEEN LINKED WITH SOCIAL STRESS, THE CHRONIC SOCIAL STRESS PARADIGMS FOR MODELING PSYCHIATRIC DISORDERS IN ANIMALS HAVE THUS BEEN DEVELOPED. CHRONIC SOCIAL ISOLATION IN ANIMAL MODELS GENERALLY CAUSES CHANGES IN HYPOTHALAMIC-PITUITARY-ADRENAL AXIS FUNCTIONING, ASSOCIATED WITH ANXIETY- AND DEPRESSIVE-LIKE BEHAVIORS. ALSO, THIS CHRONIC STRESS CAUSES DOWNREGULATION OF BDNF PROTEIN AND MRNA IN THE HIPPOCAMPUS, A STRESS-SENSITIVE BRAIN REGION CLOSELY RELATED TO THE PATHOPHYSIOLOGY OF DEPRESSION. IN THIS REVIEW, WE DISCUSS THE CURRENT KNOWLEDGE REGARDING THE STRUCTURE, FUNCTION, INTRACELLULAR SIGNALING, INTER-INDIVIDUAL DIFFERENCES AND EPIGENETIC REGULATION OF BDNF IN BOTH PHYSIOLOGICAL CONDITIONS AND DEPRESSION AND CHANGES IN CORTICOSTERONE LEVELS, AS A MARKER OF STRESS RESPONSE. SINCE BDNF LEVELS ARE AGE DEPENDENT IN HUMANS AND RODENTS, THIS REVIEW WILL ALSO HIGHLIGHT THE EFFECTS OF ADOLESCENT AND ADULT CHRONIC SOCIAL ISOLATION MODELS OF BOTH GENDERS ON THE BDNF EXPRESSION. 2017 17 432 30 ANTIDEPRESSANT TREATMENT IS ASSOCIATED WITH EPIGENETIC ALTERATIONS IN THE PROMOTER OF P11 IN A GENETIC MODEL OF DEPRESSION. P11 (S100A10) HAS BEEN ASSOCIATED WITH THE PATHOPHYSIOLOGY OF DEPRESSION BOTH IN HUMAN AND RODENT MODELS. DIFFERENT TYPES OF ANTIDEPRESSANTS HAVE BEEN SHOWN TO INCREASE P11 LEVELS IN DISTINCT BRAIN REGIONS AND P11 GENE THERAPY WAS RECENTLY PROVEN EFFECTIVE IN REVERSING DEPRESSIVE-LIKE BEHAVIOURS IN MICE. HOWEVER, THE MOLECULAR MECHANISMS THAT GOVERN P11 GENE EXPRESSION IN RESPONSE TO ANTIDEPRESSANTS STILL REMAIN ELUSIVE. IN THIS STUDY WE REPORT DECREASED LEVELS OF P11, ASSOCIATED WITH HIGHER DNA METHYLATION IN THE PROMOTER REGION, IN THE PREFRONTAL CORTEX OF THE FLINDERS SENSITIVE LINE (FSL) GENETIC RODENT MODEL OF DEPRESSION. THIS HYPERMETHYLATED PATTERN WAS REVERSED TO NORMAL, AS INDICATED BY THE CONTROL LINE, AFTER CHRONIC ADMINISTRATION OF ESCITALOPRAM (A SELECTIVE SEROTONIN REUPTAKE INHIBITOR; SSRI). THE ESCITALOPRAM-INDUCED HYPOMETHYLATION WAS ASSOCIATED WITH BOTH AN INCREASE IN P11 GENE EXPRESSION AND A REDUCTION IN MRNA LEVELS OF TWO DNA METHYLTRANSFERASES THAT HAVE BEEN SHOWN TO MAINTAIN DNA METHYLATION IN ADULT FOREBRAIN NEURONS (DNMT1 AND DNMT3A). IN CONCLUSION, OUR DATA FURTHER SUPPORT A ROLE FOR P11 IN DEPRESSION-LIKE STATES AND SUGGEST THAT THIS GENE IS CONTROLLED BY EPIGENETIC MECHANISMS THAT CAN BE AFFECTED BY ANTIDEPRESSANT TREATMENT. 2012 18 3892 47 L-ACETYLCARNITINE CAUSES RAPID ANTIDEPRESSANT EFFECTS THROUGH THE EPIGENETIC INDUCTION OF MGLU2 RECEPTORS. EPIGENETIC MECHANISMS ARE INVOLVED IN THE PATHOPHYSIOLOGY OF DEPRESSIVE DISORDERS AND ARE UNIQUE POTENTIAL TARGETS FOR THERAPEUTIC INTERVENTION. THE ACETYLATING AGENT L-ACETYLCARNITINE (LAC), A WELL-TOLERATED DRUG, BEHAVES AS AN ANTIDEPRESSANT BY THE EPIGENETIC REGULATION OF TYPE 2 METABOTROPIC GLUTAMATE (MGLU2) RECEPTORS. IT CAUSED A RAPID AND LONG-LASTING ANTIDEPRESSANT EFFECT IN FLINDERS SENSITIVE LINE RATS AND IN MICE EXPOSED TO CHRONIC UNPREDICTABLE STRESS, WHICH, RESPECTIVELY, MODEL GENETIC AND ENVIRONMENTALLY INDUCED DEPRESSION. IN BOTH MODELS, LAC INCREASED LEVELS OF ACETYLATED H3K27 BOUND TO THE GRM2 PROMOTER AND ALSO INCREASED ACETYLATION OF NF-KB-P65 SUBUNIT, THEREBY ENHANCING THE TRANSCRIPTION OF GRM2 GENE ENCODING FOR THE MGLU2 RECEPTOR IN HIPPOCAMPUS AND PREFRONTAL CORTEX. IMPORTANTLY, LAC REDUCED THE IMMOBILITY TIME IN THE FORCED SWIM TEST AND INCREASED SUCROSE PREFERENCE AS EARLY AS 3 D OF TREATMENT, WHEREAS 14 D OF TREATMENT WERE NEEDED FOR THE ANTIDEPRESSANT EFFECT OF CHLORIMIPRAMINE. MOREOVER, THERE WAS NO TOLERANCE TO THE ACTION OF LAC, AND THE ANTIDEPRESSANT EFFECT WAS STILL SEEN 2 WK AFTER DRUG WITHDRAWAL. CONVERSELY, NF-KB INHIBITION PREVENTED THE INCREASE IN MGLU2 EXPRESSION INDUCED BY LAC, WHEREAS THE USE OF A HISTONE DEACETYLASE INHIBITOR SUPPORTED THE EPIGENETIC CONTROL OF MGLU2 EXPRESSION. FINALLY, LAC HAD NO EFFECT ON MGLU2 KNOCKOUT MICE EXPOSED TO CHRONIC UNPREDICTABLE STRESS, AND A SINGLE INJECTION OF THE MGLU2/3 RECEPTOR ANTAGONIST LY341495 PARTIALLY BLOCKED LAC ACTION. THE RAPID AND LONG-LASTING ANTIDEPRESSANT ACTION OF LAC STRONGLY SUGGESTS A UNIQUE APPROACH TO EXAMINE THE EPIGENETIC HYPOTHESIS OF DEPRESSIVE DISORDERS IN HUMANS, PAVING THE WAY FOR MORE EFFICIENT ANTIDEPRESSANTS WITH FASTER ONSET OF ACTION. 2013 19 3708 25 INFLUENCE OF PHARMACOLOGICAL AND EPIGENETIC FACTORS TO SUPPRESS NEUROTROPHIC FACTORS AND ENHANCE NEURAL PLASTICITY IN STRESS AND MOOD DISORDERS. STRESS-INDUCED MAJOR DEPRESSION AND MOOD DISORDERS ARE CHARACTERIZED BY BEHAVIOURAL ABNORMALITIES AND PSYCHIATRIC ILLNESS, LEADING TO DISABILITY AND IMMATURE MORTALITY WORLDWIDE. NEUROBIOLOGICAL MECHANISMS OF STRESS AND MOOD DISORDERS ARE DISCUSSED CONSIDERING RECENT FINDINGS, AND CHALLENGES TO ENHANCE PHARMACOLOGICAL EFFECTS OF ANTIDEPRESSANT, AND MOOD STABILIZERS. PHARMACOLOGICAL ENHANCEMENT OF KETAMINE AND SCOPOLAMINE REGULATES DEPRESSION AT THE MOLECULAR LEVEL, INCREASING SYNAPTIC PLASTICITY IN PREFRONTAL REGIONS. BLOOD-DERIVED NEUROTROPHIC FACTORS FACILITATE MOOD-DEFICIT SYMPTOMS. EPIGENETIC FACTORS MAINTAIN STRESS-RESILIENCE IN HIPPOCAMPAL REGION. REGULATION OF NEUROTROPHIC FACTORS BLOCKADES STRESS, AND ENHANCES NEURONAL SURVIVAL THOUGH IT PARALYZES LIMBIC REGIONS. MOLECULAR AGENTS AND NEUROTROPHIC FACTORS ALSO CONTROL BEHAVIORAL AND SYNAPTIC PLASTICITY IN ADDICTION AND STRESS DISORDERS. FUTURE RESEARCH ON NEURONAL DYNAMICS AND CELLULAR ACTIONS CAN BE DIRECTED TO OBTAIN THE ETIOLOGY OF SYNAPTIC DYSREGULATION IN MOOD DISORDER AND STRESS. FOR THE FIRST TIME, THE CURRENT REVIEW CONTRIBUTES TO THE LITERATURE OF SYNAPTIC PLASTICITY REPRESENTING THE ROLE OF EPIGENETIC MECHANISMS AND GLUCOCORTICOID RECEPTORS TO PREDICT DEPRESSION AND ANXIETY IN CLINICAL CONDITIONS. 2019 20 1999 28 EPIGENETIC AND NEURONAL ACTIVITY MARKERS SUGGEST THE RECRUITMENT OF THE PREFRONTAL CORTEX AND HIPPOCAMPUS IN THE THREE-HIT MODEL OF DEPRESSION IN MALE PACAP HETEROZYGOUS MICE. DEPRESSION AND ITS INCREASING PREVALENCE CHALLENGE PATIENTS, THE HEALTHCARE SYSTEM, AND THE ECONOMY. WE RECENTLY CREATED A MOUSE MODEL BASED ON THE THREE-HIT CONCEPT OF DEPRESSION. AS GENETIC PREDISPOSITION (FIRST HIT), WE APPLIED PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE HETEROZYGOUS MICE ON CD1 BACKGROUND. MATERNAL DEPRIVATION MODELED THE EPIGENETIC FACTOR (SECOND HIT), AND THE CHRONIC VARIABLE MILD STRESS WAS THE ENVIRONMENTAL FACTOR (THIRD HIT). FLUOXETINE TREATMENT WAS APPLIED TO TEST THE PREDICTIVE VALIDITY OF OUR MODEL. WE AIMED TO EXAMINE THE DYNAMICS OF THE EPIGENETIC MARKER ACETYL-LYSINE 9 H3 HISTONE (H3K9AC) AND THE NEURONAL ACTIVITY MARKER FOSB IN THE PREFRONTAL CORTEX (PFC) AND HIPPOCAMPUS. FLUOXETINE DECREASED H3K9AC IN PFC IN NON-DEPRIVED ANIMALS, BUT A HISTORY OF MATERNAL DEPRIVATION ABOLISHED THE EFFECT OF STRESS AND SSRI TREATMENT ON H3K9AC IMMUNOREACTIVITY. IN THE HIPPOCAMPUS, STRESS DECREASED, WHILE SSRI INCREASED H3K9AC IMMUNOSIGNAL, UNLIKE IN THE DEPRIVED MICE, WHERE THE OPPOSITE EFFECT WAS DETECTED. FOSB IN STRESS WAS STIMULATED BY FLUOXETINE IN THE PFC, WHILE IT WAS INHIBITED IN THE HIPPOCAMPUS. THE FOSB IMMUNOREACTIVITY WAS ALMOST COMPLETELY ABOLISHED IN THE HIPPOCAMPUS OF THE DEPRIVED MICE. THIS STUDY SHOWED THAT FOSB AND H3K9AC WERE MODULATED IN A TERRITORY-SPECIFIC MANNER BY EARLY LIFE ADVERSITIES AND LATER LIFE STRESS INTERACTING WITH THE EFFECT OF FLUOXETINE THERAPY SUPPORTING THE RELIABILITY OF OUR MODEL. 2022